Pharmaceutical Commerce - April 2010 - (Page 28)

Executive Training & Development Executives on the Move PHARMA MANUFACTURERS Amgen (Thousand Oaks, CA) has promoted Robert Bradway, EVP and CFO, to the role of President and COO. He will be responsible for the company’s Global Commercial Operations, Manufacturing Operations, Strategy and Corporate Development, IT, Global Government Affairs and Compliance. The company also announced that George Morrow, EVP of Global Commercial Operations, will retire, effective January 31, 2011. Until that time, he will be reporting to Kevin Sharer, CEO, and will be involved in the preparations for the launch of Prolia (denosumab) and other projects. Also, Michael Kelly, Amgen VP of finance and chief accounting officer, will serve as acting CFO. Pedro Lichtinger has been appointed President and CEO at Optimer Pharmaceuticals (San Diego), as co-founder Michael Chang, PhD, will move to a role as chairman of the board and a consultant to the company. Lichtinger has had a 14-year career at Pfizer, most recently as President of Pfizer’s Global Primary Care Business Unit, and before that as Area President, Europe. He has degrees from the National University of Mexico and the Wharton School. Cempra Pharmaceuticals (Chapel Hill, NC) has appointed Mark Hahn as Executive VP and CFO. Prior to joining the company, Hahn was CFO of Athenix Corp., a leading agricultural biotechnology company where he led the company in their $400 million merger with Bayer CropScience. His undergraduate degree is from University of WisconsinMadison. Cempra has antibacterials in Phase I and II development. Dr Georges Gemayel has been appointed Executive Chairman at FodRx Pharmaceuticals (Cambridge, MA). Dr. Gemayel has previously served as CEO of Altus Pharmaceuticals, and as an Executive Vice President at Genzyme. FoldRx Pharmaceuticals is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis). It is expecting to file marketing applications later this year. Jeffrey Dayno, MD, is now Chief Medical Officer at Labopharm (US HQ: Princeton, NJ), where he will be responsible for leading the company’s clinical efforts and medical affairs functions, as it prepares to commercialize Olpetro (trazodone hydrochloride) in the US market (see p. 23). Previously, Dr. Dayno worked at Cephalon where he was VP, Medical Services. 28 APRIL 2010 PHARMA SERVICE PROVIDERS DDN (Menomenee Falls, MN) has elevated its former COO, Mark Wiesman, to president. Weisman joined DDN, a leading provider of outsourced services to biopharma, in 2007 as VP Finance. He has previous work experience at VPI, LLC and Ernst & Young, and has degrees from Marquette University and Northwestern’s Kellogg Graduate School of Business. Weisman has subsequently made several promotions and hires: Dan Dietz, from VP Finance to VP of Order to Cash Operations; Rob Klinck from business development manager to VP of Sales and Marketing; Dr. Janett Gray, from senior director to VP, Quality and Regulatory; and Peg Heinen from director, HR, to VP, HR. New hires are Pat McGinn as VP, Client Initiatives, and Tom Donahue as Controller. The CMR Institute (Roanoke, VA), the leading provider of nonbranded biopharmaceutical education, has announced that its SVP of Learning Strategy and Innovation, Michelle O’Connor, has been appointed to the Center for Instructional Solutions in Industry and Education (CITSIE) advisory board at Virginia Tech University. CITSIE is a research and development center focused on providing instructional technology research and outreach in cooperation with primary and higher educational institutions, community health settings, government agencies, and the private sector. The National Assn. of Chain Drug Stores (Alexandria, VA) has named Sandra Kay Guckian, MS, RPh, as head of its state government affairs team. Previously, she served as VP and deputy director of state government affairs, and has had a 13-year career at the organization. The Maxcess Managed Markets unit of Publicis Health Care Communications North America (New York) has appointed James Harmon as Executive Vice President and Managing Director. Maxcess is a specialty provider of strategic marketing insight, planning, research and communication services to pharma. Previously, Harmon was an executive with Campbell Alliance, and before that, VP of Managed Markets at Organon, Inc. Prime Therapeutics (St. Paul, MN) has named Eric Elliott as President and CEO. He comes to Prime from CIGNA Pharmacy Management, where he was president, Prime Therapeutics is a PBM managing 14.7 million covered lives, and is owned by 11 Blue Cross and Blue Shield plans and affiliates. Elliott has degrees from Temple University. David Mounts, formerly EVP of supply chain at Domino’s Pizza, has assumed the CEO position at Inmar (Winston-Salem, NC). In life sciences, Inmar manages reverse logistics, promotional transactions and claims processing. Mounts’ career began at UPS, and he has degrees from the University of Nevada at Las Vegas and the Wharton School. At Veeva Systems (Pleasanton, CA), a CRM vendor for life sciences, Dan Goldsmith has been hired at VP of Europe, and Tim Cabral as CFO. Goldsmith has prior experience at IBM/PricewaterhouseCoopers, and Cabral at Walsh Wireless and, earlier, Peoplesoft. Blair Gibson has accepted a position as VP, Brand Solutions for the Global Commercial Solutions unit of Quintiles (Research Triangle Park, NC), where he will work with clients to optimize product lifecycles. Previously, he was executive director for portfolio strategy at Merck, and before that, a senior director at Sanofi Aventis. Quintiles has also announced the promotion of Geoff Owen as SVP, Global Business Development, for the Commercial Solutions unit. He has worked in Innovex (the former identity of the Commercial unit), and NovaQuest, Quintiles partnering arm. Qforma (Santa Fe, NM) has appointed Judy Stein as Director, Client Services, where she will develop customized project plans to clients. Previously, she worked as a senior manager at GE Healthcare. Qforma applies advanced mathematics for quantifying large data flows to eliminate inefficiencies in life sciences sales and marketing. PC Dicerna Pharmaceuticals (Watertown, MA) has appointed Douglas Fambrough, PhD, as CEO of the second-generation RNA interference company. Former CEO and cofounder James Jenson, PhD, will continue as a member of the company’s board of directors. In conjunction with the appointment, Dr Fambrough is stepping down from his role as a general partner at Oxford Bioscience Partners, where he has specialized in financing life science companies since 1999. Akrimax Pharmaceuticals (Cranford, NJ) has appointed Neil Larimer as VP, Business Development & Manufacturing Alliances. Previously, he was senior director, North America - Sales & Marketing for DPT Laboratories. Akrimax Pharmaceuticals, LLC is a privately-held, fully-integrated nextgeneration specialty pharmaceutical company that acquires, markets and develops products to address disease states related to “metabolic syndrome.” The company also owns a worldclass manufacturing plant in Rouses Point, NY, acquired from Wyeth in January 2008. Frank Condella, i n t e r i m C E O o f Columbia Laboratories (Livingston, NJ), has agreed to stay on as permanent CEO and president. The company is in the process of negotiating the sale of its progesterone assets to Watson Pharmaceuticals, while it pursues novel drug delivery technologies. Condella is currently non-executive chairman of SkyePharma in addition to his Columbia position. Celgene Corp. (Summit, NJ) has announced a senior management succession plan. Dr. Sol Barer, currently CEO, will be appointed Executive Chairman at the company’s June annual meeting, and Robert Hugin, currently president and COO, will be appointed CEO. Commenting on the succession, Dr. Barer said, “I am extremely pleased to pass the leadership of Celgene to Bob Hugin with whom, I have worked in close partnership over the last eleven years. Bob brings strong leadership, experience, and continuity to our business that enables Celgene to continue our mission to become the premier biopharmaceutical company.” Michael Polito, f o r m e r l y t h e U S Controller of Barr Pharmaceuticals prior to its acquisition by Teva, has joined Heritage Pharmaceuticals (Edison, NJ) as CFO. Heritage Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. PHARMA EUTICAL OMMERCE LIKE WHAT YOU ARE READING? If you want more, you must subscribe. Register online at www. PharmaceuticalCommerce.com www.PharmaceuticalCommerce.com http://www.PharmaceuticalCommerce.com http://www.PharmaceuticalCommerce.com http://www.PharmaceuticalCommerce.com http://www.PharmaceuticalCommerce.com

Table of Contents for the Digital Edition of Pharmaceutical Commerce - April 2010

Pharmaceutical Commerce - April 2010
Contents
Editorial
Op-Ed
Top News
Business & Finance
BrandMarketing | Communications
Supply Chain | Logistics
Information Technology
Packaging & Drug Delivery
Legal | Regulatory
Executive Training & Development
Editorial Index & Meetings

Pharmaceutical Commerce - April 2010

http://www.nxtbook.com/nxtbooks/pharmcomm/201911
http://www.nxtbook.com/nxtbooks/pharmcomm/201909
http://www.nxtbook.com/nxtbooks/pharmcomm/201906
http://www.nxtbook.com/nxtbooks/pharmcomm/201903
http://www.nxtbook.com/nxtbooks/pharmcomm/201811
http://www.nxtbook.com/nxtbooks/pharmcomm/201809
http://www.nxtbook.com/nxtbooks/pharmcomm/201806
http://www.nxtbook.com/nxtbooks/pharmcomm/20180304
http://www.nxtbook.com/nxtbooks/pharmcomm/20171112
http://www.nxtbook.com/nxtbooks/pharmcomm/20170910
http://www.nxtbook.com/nxtbooks/pharmcomm/20170708
http://www.nxtbook.com/nxtbooks/pharmcomm/20170506
http://www.nxtbook.com/nxtbooks/pharmcomm/20170304
http://www.nxtbook.com/nxtbooks/pharmcomm/20170102
http://www.nxtbook.com/nxtbooks/pharmcomm/20161112
http://www.nxtbook.com/nxtbooks/pharmcomm/20160910
http://www.nxtbook.com/nxtbooks/pharmcomm/20160708
http://www.nxtbook.com/nxtbooks/pharmcomm/20160506
http://www.nxtbook.com/nxtbooks/pharmcomm/20160304
http://www.nxtbook.com/nxtbooks/pharmcomm/20160102
http://www.nxtbook.com/nxtbooks/pharmcomm/20151112
http://www.nxtbook.com/nxtbooks/pharmcomm/20150910
http://www.nxtbook.com/nxtbooks/pharmcomm/20150708
http://www.nxtbook.com/nxtbooks/pharmcomm/20150506
http://www.nxtbook.com/nxtbooks/pharmcomm/20150304
http://www.nxtbook.com/nxtbooks/pharmcomm/20150102
http://www.nxtbook.com/nxtbooks/pharmcomm/20141112
http://www.nxtbook.com/nxtbooks/pharmcomm/coldchaindirectory2014
http://www.nxtbook.com/nxtbooks/pharmcomm/20140910
http://www.nxtbook.com/nxtbooks/pharmcomm/20140708
http://www.nxtbook.com/nxtbooks/pharmcomm/20140506
http://www.nxtbook.com/nxtbooks/pharmcomm/20140304
http://www.nxtbook.com/nxtbooks/pharmcomm/20140102
http://www.nxtbook.com/nxtbooks/pharmcomm/dataservicedirectory
http://www.nxtbook.com/nxtbooks/pharmcomm/20131112
http://www.nxtbook.com/nxtbooks/pharmcomm/20130910_hubreport
http://www.nxtbook.com/nxtbooks/pharmcomm/20130910
http://www.nxtbook.com/nxtbooks/pharmcomm/20130708
http://www.nxtbook.com/nxtbooks/pharmcomm/20130506
http://www.nxtbook.com/nxtbooks/pharmcomm/coldchain2013
http://www.nxtbook.com/nxtbooks/pharmcomm/20130304
http://www.nxtbook.com/nxtbooks/pharmcomm/20130102
http://www.nxtbook.com/nxtbooks/pharmcomm/20121112
http://www.nxtbook.com/nxtbooks/pharmcomm/20120910
http://www.nxtbook.com/nxtbooks/pharmcomm/20120708
http://www.nxtbook.com/nxtbooks/pharmcomm/20120506
http://www.nxtbook.com/nxtbooks/pharmcomm/20120506_coldchain
http://www.nxtbook.com/nxtbooks/pharmcomm/20120304
http://www.nxtbook.com/nxtbooks/pharmcomm/20120102
http://www.nxtbook.com/nxtbooks/pharmcomm/20111112
http://www.nxtbook.com/nxtbooks/pharmcomm/20110910
http://www.nxtbook.com/nxtbooks/pharmcomm/20110708
http://www.nxtbook.com/nxtbooks/pharmcomm/20110506
http://www.nxtbook.com/nxtbooks/pharmcomm/20110304
http://www.nxtbook.com/nxtbooks/pharmcomm/20110102
http://www.nxtbook.com/nxtbooks/pharmcomm/20101112
http://www.nxtbook.com/nxtbooks/pharmcomm/20100910
http://www.nxtbook.com/nxtbooks/pharmcomm/20100708
http://www.nxtbook.com/nxtbooks/pharmcomm/20100506
http://www.nxtbook.com/nxtbooks/pharmcomm/201004
http://www.nxtbook.com/nxtbooks/pharmcomm/201003
http://www.nxtbook.com/nxtbooks/pharmcomm/20100102
http://www.nxtbook.com/nxtbooks/pharmcomm/20091112
http://www.nxtbookMEDIA.com